SORT OUT V: Comparison of drug-eluting stents: One with degradable polymer releasing biolimus and the other a permanent polymer sirolimus stent.

SORT OUT V randomized trial (Odense University Hospital, Denmark) compared Nobori stent, a drug-eluting stent with biodegradable polymer eluting biolimus, versus CYPHER a drug-eluting stent with permanent polymer in the real world. Danish researchers used a non-inferiority design, by means of a primary objective of the study, the combined rate of major cardiac events (cardiac death, myocardial infarction and definite in-stent thrombosis and reintervention in treated vessel) at nine months follow up. A total of 2400 patients from July 2009 to January 2011 were included (1:1 randomization). The primary endpoint was 4.1% for degradable polymer and 3.2% for the group with permanent polymer and inferiority hypothesis cannot be ruled out but without statistical power to infer superiority of permanent polymer stent. At 12 months, the major cardiac events rate was 5.4% and 4.5% for degradable polymer stent and permanent polymer stent, respectively (p = 0.28). The annual rate of thrombosis was very low (0.8% with degradable polymer and 0.2% with permanent polymer, p = 0.07). The annual vessel reintervention observed in both groups was very encouraging, (4.2% with degradable polymer and 3.1% with permanent polymer). No rate differences were observed in heart attack or cardiac death.

Dr. Spencer King (Atlanta, Georgia, USA) commented: “First of all, these results are spectacular, regardless of used stent. It is likely that the true test of any degradable polymer stent is the reduction of events the year after discontinuation of clopidogrel. “We will wait to test their long-term behavior.”

christiansen-SORT-OUT-V
E. H. Christiansen
2012-05-17

More articles by this author

CIBELES: Xience V comparative study vs Cypher for the treatment of total chronic occlusions.

Spanish-Portuguese multicentre CIBELES study (Raul Moreno, Madrid, Spain) compared two drug-eluting stents - an everolimus (Xience V, Abbott Vascular, USA) and a sirolimus-releasing eluting...

EVOLUTION: Comparative study of non-inferiority of two sirolimus eluting stents: One with permanent polymer and the other with degradable polymer.

The EVOLUTION study, (Dr. Junbo Ge, Shanghai Institute, China), compared two sirolimus-eluting stents, one with permanent polymer (Cypher Select, Cordis Corporation, Miami Lakes, Florida,...

ROMA II RELOAD: Additional charge of statin (rosuvastatin 40 mg or atorvastatin 80 mg within 24 hours of procedure) in patients on whom elective...

ROMA II RELOAD multicenter study (General Hospital Umberto I, University of Rome, Rome, Italy) assessed the impact of an additional charge of statin in...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...